Cytek Biosciences (CTKB) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Executive summary
Annual meeting scheduled for June 10, 2026, with virtual participation available to shareholders.
Shareholders are encouraged to review proxy materials and vote by June 9, 2026.
Voting matters and shareholder proposals
Election of three Class II director nominees for three-year terms expiring at the 2029 annual meeting.
Advisory vote to approve executive compensation for the year ended December 31, 2025.
Ratification of Deloitte & Touche LLP as independent auditor for the fiscal year ending December 31, 2026.
Provision for any other business that may properly come before the meeting.
Board of directors and corporate governance
Director nominees are Vera Imper, Ph.D., Glenn P. Muir, and Ming Yan, Ph.D.
Each nominee is proposed for a three-year term, subject to earlier death, resignation, or removal.
Latest events from Cytek Biosciences
- Q3 2024 revenue up 7% year-over-year, net income positive, and cash reserves strong.CTKB
Q3 20248 Jul 2026 - Q1 revenue dropped 7.6%-8%, but APAC and service revenue grew and liquidity stayed strong.CTKB
Q1 20258 Jul 2026 - Q1 2026 delivered robust growth, recurring revenue gains, and global clinical expansion.CTKB
Singular Research’s Las Vegas Invitational Conference15 Jun 2026 - Director elections, compensation, and auditor ratification all approved; Q&A followed.CTKB
AGM 202610 Jun 2026 - Record Q4 revenue and recurring growth set the stage for 2–5% expansion in 2026.CTKB
Q4 202523 May 2026 - Q1 2026 revenue up 6% to $44.1M, recurring revenue at 35%, net loss widened to $18.9M.CTKB
Q1 202623 May 2026 - Achieved 1% revenue growth in 2025, driven by innovation and global expansion.CTKB
TD Cowen 46th Annual Health Care Conference23 May 2026 - Director elections, executive pay, and auditor ratification headline the 2026 proxy agenda.CTKB
Proxy filing28 Apr 2026 - Q2 2024 revenue up sequentially, U.S. sales down, EMEA/APAC and service segments grew.CTKB
Q2 20242 Feb 2026